This study was to explore the preventive effect of esketamine on postpartum depression (PPD) in cesarean section, and to evaluate the safety of the drug

Studies have shown that esketamine can treat clinical refractory depression, the drug takes effect quickly, can quickly eliminate the patient's suicide intention, low-dose maintenance treatment is conducive to the stability of the patient's condition, and less adverse reactions, is the current hot spot of antidepressant drug research. Esketamine has been approved by FDA for the treatment of refractory and suicidal depression, but can it effectively prevent and treat postpartum depression? It is not clear. Based on this, this study aims to explore the preventive effect of prophylactic administration of esketamine on postpartum depression in cesarean section, and evaluate the safety of the drug.

Inclusion Criteria:

• Elective cesarean section;
• 18-40 years;
• Primipara;
• Singleton pregnancy;
• Sign informed consent.

Exclusion Criteria:

• American Society of Anesthesiologists (ASA) grade III and above;
• Intracranial hypertension;
• Hypertension;
• Severe heart disease;
• Hyperthyroidism patients without treatment or insufficient treatment;
• Liver and kidney dysfunction;
• Preeclampsia or eclampsia;
• Mental disorder, mental retardation;
• Drug abuse and alcoholism;
• Contraindication of intraspinal anesthesia;
• The preoperative EPDS score ≥10;
• Participated in other clinical studies.

The objects of this observation were puerpera with cesarean section

1. Assign a researcher to determine the order of patients and coordinate the relationship between researchers;
2. For each patient, an anesthesiologist was assigned to manage anesthesia and collect intraoperative data;
3. A researcher who was not aware of the protocol was assigned to conduct preoperative evaluation and postoperative follow-up, and received training on evaluation methods before the study.